SEARCH

SEARCH BY CITATION

References

  • 1
    Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial [Research Support, U.S. Gov't, Non-P.H.S.]. J Invest Dermatol 1977; 68: 328335.
  • 2
    Weberschock T, Strametz R, Lorenz M et al. Interventions for mycosis fungoides [Meta-Analysis Research Support, Non-U.S. Gov't Review]. Cochrane Database Syst Rev 2012(9)CD008946.
  • 3
    Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy [Comparative Study Randomized Controlled Trial]. Arch Dermatol 2007; 143: 578584.
  • 4
    Young AR, Magnus IA, Davies AC, Smith NP. A comparison of the phototumorigenic potential of 8-MOP and 5-MOP in hairless albino mice exposed to solar simulated radiation [Comparative Study Research Support, Non-U.S. Gov't]. Br J Dermatol 1983; 108: 507518.
  • 5
    Gibbs NK, Young AR, Magnus IA. Failure of UVR dose reciprocity for skin tumorigenesis in hairless mice treated with 8-methoxypsoralen [Research Support, Non-U.S. Gov't]. Photochem Photobiol 1985; 42: 3942.
  • 6
    Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL. Cutaneous squamous-cell carcinoma in patients treated with PUVA [Research Support, U.S. Gov't, P.H.S.]. N Engl J Med 1984; 310: 11561161.
  • 7
    Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study [Multicenter Study Research Support, U.S. Gov't, P.H.S.]. Cancer 1994; 73: 27592764.
  • 8
    Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment [Research Support, U.S. Gov't, P.H.S.]. J Invest Dermatol 1988; 91: 120124.
  • 9
    Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study [Multicenter Study Research Support, U.S. Gov't, P.H.S.]. N Engl J Med 1997; 336: 10411045.
  • 10
    Klecak G, Urbach F, Urwyler H. Fluoroquinolone antibacterials enhance UVA-induced skin tumors. J Photochem Photobiol B 1997; 37: 174181.
  • 11
    Hannuksela-Svahn A, Pukkala E, Koulu L, Jansen CT, Karvonen J. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA [Research Support, Non-U.S. Gov't]. J Am Acad Dermatol 1999; 40 (5 Pt 1): 694696.
  • 12
    Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis [Research Support, Non-U.S. Gov't]. Br J Dermatol 1999; 141: 497501.
  • 13
    Hannuksela A, Pukkala E, Hannuksela M, Karvonen J. Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA [Research Support, Non-U.S. Gov't]. J Am Acad Dermatol 1996; 35 (5 Pt 1): 685689.
  • 14
    Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Berne B. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report [Comparative Study]. Arch Dermatol 1992; 128: 13411344.
  • 15
    Perrett CM, Walker SL, O'Donovan P et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008; 159: 198204.
  • 16
    Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens [Research Support, Non-U.S. Gov't]. J Am Acad Dermatol 1999; 40 (2 Pt 1): 177186.
  • 17
    Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506509.
  • 18
    Molina BD, Leiro MG, Pulpon LA et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation [Research Support, Non-U.S. Gov't]. Transplant Proc 2010; 42: 30013005.
  • 19
    Haylett AK, Felton S, Denning DW, Rhodes LE. Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. Br J Dermatol 2013; 168: 179185.
  • 20
    Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America [Practice Guideline]. Clin Infect Dis 2008; 46: 327360.
  • 21
    Vadnerkar A, Nguyen MH, Mitsani D et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients [Research Support, N.I.H., Extramural]. J Heart Lung Transplant 2010; 29: 12401244.
  • 22
    Feist A, Lee R, Osborne S, Lane J, Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012; 31: 11771181.
  • 23
    Singer JP, Boker A, Metchnikoff C et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. J Heart Lung Transplant 2012; 31: 694699.
  • 24
    Cowen EW, Nguyen JC, Miller DD et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole [Case Reports Multicenter Study Research Support, N.I.H., Intramural]. J Am Acad Dermatol 2010; 62: 3137.
  • 25
    McLaughlin JM, Equils O, Somerville KT et al. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transpl Infect Dis 2013; 15: 329343.
  • 26
    Zwald FO, Spratt M, Lemos BD et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38: 13691374.
  • 27
    Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity [Case Reports]. Arch Dermatol 2010; 146: 300304.
  • 28
    Johnson BE, Gibbs NK, Ferguson J. Quinolone antibiotic with potential to photosensitize skin tumorigenesis. J Photochem Photobiol B 1997; 37: 171173.
  • 29
    Cadet J, Mouret S, Ravanat JL, Douki T. Photoinduced damage to cellular DNA: direct and photosensitized reactions [Review]. Photochem Photobiol 2012; 88: 10481065.
  • 30
    Stern RS, Bolshakov S, Nataraj AJ, Ananthaswamy HN. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. J Invest Dermatol 2002; 119: 522526.
  • 31
    Lhiaubet-Vallet V, Bosca F, Miranda MA. Photosensitized DNA damage: the case of fluoroquinolones [Research Support, Non-U.S. Gov't Review]. Photochem Photobiol 2009; 85: 861868.
  • 32
    de Guidi G, Bracchitta G, Catalfo A. Photosensitization reactions of fluoroquinolones and their biological consequences [Review]. Photochem Photobiol 2011; 87: 12141229.
  • 33
    Traynor NJ, Gibbs NK. The phototumorigenic fluoroquinolone lomefloxacin photosensitizes pyrimidine dimer formation in human keratinocytes in vitro [Research Support, Non-U.S. Gov't]. Photochem Photobiol 1999; 70: 957959.
  • 34
    Cadet J, Douki T, Ravanat JL, Di Mascio P. Sensitized formation of oxidatively generated damage to cellular DNA by UVA radiation [Research Support, Non-U.S. Gov't Review]. Photochem Photobiol Sci 2009; 8: 903911.
  • 35
    Cadet J, Douki T, Ravanat JL. Oxidatively generated damage to the guanine moiety of DNA: mechanistic aspects and formation in cells [Review]. Acc Chem Res 2008; 41: 10751083.
  • 36
    Sauvaigo S, Douki T, Odin F, Caillat S, Ravanat JL, Cadet J. Analysis of fluoroquinolone-mediated photosensitization of 2′-deoxyguanosine, calf thymus and cellular DNA: determination of type-I, type-II and triplet-triplet energy transfer mechanism contribution. Photochem Photobiol 2001; 73: 230237.
  • 37
    Marrot L, Belaidi JP, Jones C et al. Molecular responses to photogenotoxic stress induced by the antibiotic lomefloxacin in human skin cells: from DNA damage to apoptosis. J Invest Dermatol 2003; 121: 596606.
  • 38
    O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage [Research Support, Non-U.S. Gov't]. Science 2005; 309: 18711874.
  • 39
    Hofbauer GF, Attard NR, Harwood CA et al. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine [Research Support, Non-U.S. Gov't]. Am J Transplant 2012; 12: 218225.
  • 40
    Epaulard O, Leccia MT, Blanche S et al. Phototoxicity and photocarcinogenesis associated with voriconazole [Research Support, Non-U.S. Gov't Review]. Med Mal Infect 2011; 41: 639645.
  • 41
    Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes [Research Support, Non-U.S. Gov't]. Biochem Pharmacol 2007; 73: 20202026.
  • 42
    Yoshida Y, Aoyama Y. Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes [Research Support, Non-U.S. Gov't]. Biochem Pharmacol 1987; 36: 229235.
  • 43
    Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans [Research Support, Non-U.S. Gov't]. Biochem J 1990; 266: 475480.
  • 44
    Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status [Comment Letter Research Support, Non-U.S. Gov't]. Clin Pharmacol Ther 2004; 75: 587588.
  • 45
    Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole [Case Reports]. Clin Exp Dermatol 2001; 26: 648653.
  • 46
    Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma [Clinical Trial, Phase I Multicenter Study Research Support, Non-U.S. Gov't]. N Engl J Med 2010; 363: 809819.
  • 47
    Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy [Letter]. N Engl J Med 2012; 366: 480481.
  • 48
    Gelot P, Dutartre H, Khammari A et al. Vemurafenib: an unusual UVA-induced photosensitivity [Letter]. Exp Dermatol 2013; 22: 297298.
  • 49
    Anforth R, Tembe V, Blumetti T, Fernandez-Penas P. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors [Research Support, Non-U.S. Gov't]. Pigment Cell Melanoma Res 2012; 25: 569572.
  • 50
    Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors [Clinical Trial, Phase I Clinical Trial, Phase II Clinical Trial, Phase III Research Support, Non-U.S. Gov't]. N Engl J Med 2012; 366: 207215.
  • 51
    Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. J Clin Oncol 2012; 30: 316321.
  • 52
    Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Sorensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Br J Cancer 2008; 99: 15221528.
  • 53
    Davis R, Wells CH, Taylor AR. Photolytic decomposition of indapamide. J Pharm Sci 1979; 68: 10631064.
  • 54
    Larue L, Dougherty N, Mintz B. Genetic predisposition of transgenic mouse melanocytes to melanoma results in malignant melanoma after exposure to a low ultraviolet B intensity nontumorigenic for normal melanocytes [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Proc Natl Acad Sci U S A 1992; 89: 95349538.
  • 55
    Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M. Photosensitizing medication use and risk of skin cancer [Research Support, Non-U.S. Gov't]. Cancer Epidemiol Biomarkers Prev 2010; 19: 29422949.
  • 56
    Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study. J Invest Dermatol 2013; 133: 19501955.
  • 57
    Gallagher RP, Hill GB, Bajdik CD et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma [Research Support, Non-U.S. Gov't]. Arch Dermatol 1995; 131: 157163.
  • 58
    Lynch AM, Guzzie PJ, Bauer D et al. Considerations on photochemical genotoxicity. II: report of the 2009 International Workshop on Genotoxicity Testing Working Group. Mutat Res 2011; 723: 91100.
  • 59
    EMA, CPMP/SWP/398/01 ‘Note for Guidance on Photosafety Testing’, London, 2002.
  • 60
    FDA/CDER Guidance for Industry. Photosafety testing, 2003.
  • 61
    Note 1. ICH guideline S10: Guidance on photosafety evaluation of pharmaceuticals, EMA/CHMP/ICH/752211/2012.
  • 62
    Bech-Thomsen N, Wulf HC. Sunbathers' application of sunscreen is probably inadequate to obtain the sun protection factor assigned to the preparation. Photodermatol Photoimmunol Photomed 1992; 9: 242244.